Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.
Saved in:
| Title: | Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study. |
|---|---|
| Authors: | Huang XY; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Shi GM; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Zheng ZT; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Sun HC; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Liang F; Department of Statistics, Zhongshan Hospital, Fudan University, Shanghai, China., Ji Y; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China., Chen Y; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Yang GH; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Hu ZQ; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Lu JC; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Meng XL; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Guo XJ; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Zhang CC; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Fan J; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Zhou J; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China. zhou.jian@zs-hospital.sh.cn. |
| Source: | BMC medicine [BMC Med] 2025 Oct 21; Vol. 23 (1), pp. 573. Date of Electronic Publication: 2025 Oct 21. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015 (Electronic) Linking ISSN: 17417015 NLM ISO Abbreviation: BMC Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
